Kintara Therapeutics, Inc. (KTRA)
After hours:
| Previous close | 0.2780 |
| Open | 0.2750 |
| Bid | 0.2505 x 1200 |
| Ask | 0.2598 x 800 |
| Day's range | 0.2500 - 0.2879 |
| 52-week range | 0.1410 - 2.0700 |
| Volume | |
| Avg. volume | 4,279,980 |
| Market cap | 16.711M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6430 |
| Earnings date | 27 Sept 2022 - 03 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.17 |
- PR Newswire
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference. The conference is being held virtually on June 21 – 22, 2022.
- PR Newswire
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's VAL-083 for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM).
- PR Newswire
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference. The conference is being held on June 15 – 16, 2022 at the Lotte New York Palace Hotel.
